Immunovant (IMVT) Revenue & Revenue Breakdown
Immunovant Revenue Highlights
0
Latest Revenue (Q)
$7.09M
Immunovant Revenue by Period
Immunovant Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2026-03-31 | - | 100.00% |
| 2025-03-31 | - | 100.00% |
| 2024-03-31 | - | 100.00% |
| 2023-03-31 | - | 100.00% |
| 2022-03-31 | - | 100.00% |
| 2021-03-31 | - | 100.00% |
| 2020-03-31 | - | 100.00% |
| 2019-03-31 | - | 100.00% |
| 2018-03-31 | - | - |
Immunovant generated - in revenue during NA 2026, up 100.00% compared to the previous quarter, and up NaN% compared to the same period a year ago.
Immunovant Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2026-06-30 | $7.09M | 100.00% |
| 2026-03-31 | - | 100.00% |
| 2025-12-31 | - | 100.00% |
| 2025-09-30 | - | 100.00% |
| 2025-06-30 | - | 100.00% |
| 2025-03-31 | - | 100.00% |
| 2024-12-31 | - | 100.00% |
| 2024-09-30 | - | 100.00% |
| 2024-06-30 | - | 100.00% |
| 2024-03-31 | - | 100.00% |
| 2023-12-31 | - | 100.00% |
| 2023-09-30 | - | 100.00% |
| 2023-06-30 | - | 100.00% |
| 2023-03-31 | - | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2022-09-30 | - | 100.00% |
| 2022-06-30 | - | 100.00% |
| 2022-03-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2021-09-30 | - | 100.00% |
| 2021-06-30 | - | 100.00% |
| 2021-03-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2020-09-30 | - | 100.00% |
| 2020-06-30 | - | 100.00% |
| 2020-03-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2019-09-30 | - | 100.00% |
| 2019-06-30 | - | 100.00% |
| 2019-03-31 | - | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2018-09-30 | - | 100.00% |
| 2018-06-30 | - | - |
Immunovant generated $7.09M in revenue during Q1 2027, up 100.00% compared to the previous quarter, and up Infinity% compared to the same period a year ago.
Immunovant Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| TGTX | TG Therapeutics | $616.29M | $240.34M |
| ANAB | AnaptysBio | $234.60M | $25.56M |
| ZBIO | Zenas BioPharma | $10.00M | $1.00M |
| ACRS | Aclaris Therapeutics | $7.83M | $1.63M |
| CGEM | Cullinan Therapeutics | - | - |
| TRAX | First Tracks Biotherapeutics | - | - |
| CABA | Cabaletta Bio | - | - |
| IMVT | Immunovant | - | $7.09M |
| ANNX | Annexon | - | - |
| QTTB | Q32 Bio | - | - |
| IMUX | Immunic | - | - |